[Transcatheter hepatic arterial embolization therapy using degradable polylactic acid microspheres].
Transcatheter hepatic arterial embolization therapy (TAE) is an established method for the treatment of hepatocellular carcinoma (HCC). We have developed a new embolus consisting of microspheres with a mean diameter of about 200 microns which are composed of biodegradable polymolecular polylactic and the anti-cancer agent, aclarubicin -HCl, in a ratio of 12% w/w. These microspheres were applied to 28 patients with inoperable HCC using the following method microspheres containing 50 mg of aclarubicin-HCl were injected through a catheter placed in the hepatic artery or one of its branches, 2 or 3 times at intervals of 2 to 4 weeks. The effectiveness was confirmed by decreased levels of serum AFP and regression of the tumor size, and the accumulated survival rate for 6 months was 83.3%.
D015250:Aclarubicin; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D002404:Catheterization; D004621:Embolization, Therapeutic / Q000379:methods*; D006499:Hepatic Artery; D006801:Humans; D007773:Lactates / Q000008:administration & dosage*; D019344:Lactic Acid; D008113:Liver Neoplasms / Q000628:therapy*; D008863:Microspheres; D009279:Naphthacenes / Q000008:administration & dosage; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*
D000903:Antibiotics, Antineoplastic; D007773:Lactates; D009279:Naphthacenes; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D015250:Aclarubicin